Jefferies reiterates Hold rating on Aurinia Pharmaceuticals stock at $10 price target

Jefferies reiterated a Hold rating and $10.00 price target on Aurinia Pharmaceuticals (NASDAQ:AUPH), dismissing the recent nearly 15% stock decline as an unwarranted reaction to a retracted FDA official's blog post questioning the efficacy of its drug Lupkynis. The firm cited strong clinical evidence and Aurinia's robust fundamentals, which are further supported by the company's strong Q2 2025 results, where it surpassed EPS and revenue expectations with $0.16 and $70 million, respectively, indicating continued financial health and growth despite recent market volatility.

Analysis

Aurinia Pharmaceuticals (AUPH) presents a notable disconnect between recent market sentiment and its underlying financial performance. The stock's recent decline of nearly 15% was triggered by a controversial, and subsequently retracted, blog post from an FDA official questioning the clinical benefit of its lead drug, Lupkynis. However, Jefferies has characterized this selloff as "unwarranted," reiterating a Hold rating and a $10.00 price target, citing strong Phase III clinical data that contradicts the official's personal view. This event overshadows the company's robust operational results, which include strong fundamentals such as an 80% gross margin. For Q2 2025, Aurinia reported significant outperformance, with revenue of $70 million surpassing forecasts by 8.92% and an EPS of $0.16 beating expectations by 14.29%. These strong earnings and revenue beats, coupled with analyst commentary, suggest the company's fundamental health remains intact despite the volatility induced by the non-official regulatory commentary.

Key Decisions for Investors

• Investors should evaluate the recent share price weakness as a potential dislocation, weighing the company's strong Q2 2025 earnings beat and 80% gross margins against the perceived regulatory risk, which has been clarified as a non-official FDA position.
• Monitor future communications from the FDA regarding Lupkynis, as any official statement could either validate the market's recent fear or confirm the selloff was an overreaction, creating a significant catalyst for the stock.
• Note that while Jefferies defended the company's clinical data, its reiterated 'Hold' rating suggests a neutral stance, implying that investors should seek further confirmation of sustained growth or resolution of the sentiment overhang before taking a strong directional position.